Related Experiment Video
Updated: Apr 11, 2026
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models
Soledad Mac Keon1, María Sol Ruiz2, Silvina Gazzaniga3
1Laboratorio de Cancerología, Fundación Instituto Leloir, Instituto de Investigaciones Bioquímicas de Buenos Aires IIBBA-CONICET , Buenos Aires , Argentina.
Abstract:
Dendritic cells (DCs) play a pivotal role in the orchestration of immune responses, and are thus key targets in cancer vaccine design. Since the 2010 FDA approval of the first cancer DC-based vaccine (Sipuleucel-T), there has been a surge of interest in exploiting these cells as a therapeutic option for the treatment of tumors of diverse origin. In spite of the encouraging results obtained in the clinic, many elements of DC-based vaccination strategies need to be optimized. In this context, the use of experimental cancer models can help direct efforts toward an effective vaccine design. This paper reviews recent findings in murine models regarding the antitumoral mechanisms of DC-based vaccination, covering issues related to antigen sources, the use of adjuvants and maturing agents, and the role of DC subsets and their interaction in the initiation of antitumoral immune responses. The summary of such diverse aspects will highlight advantages and drawbacks in the use of murine models, and contribute to the design of successful DC-based translational approaches for cancer treatment.
Insights
Dendritic cell (DC) vaccines are crucial for cancer immunotherapy. Murine models reveal insights into DC-based vaccination mechanisms, guiding improved cancer treatment strategies.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Dendritic cells (DCs) are critical for initiating immune responses and are key targets for cancer vaccine development.
- The first FDA-approved DC-based cancer vaccine (Sipuleucel-T) in 2010 spurred significant interest in DC-based cancer therapies.
- Despite clinical successes, optimizing DC-based vaccination strategies remains essential for effective tumor treatment.
Purpose of the Study:
- To review recent findings in murine models concerning the antitumoral mechanisms of DC-based vaccination.
- To identify key factors influencing DC-based vaccine efficacy, including antigen sources, adjuvants, and maturing agents.
- To evaluate the role of DC subsets and their interactions in initiating anti-tumor immune responses.
Main Methods:
- Review of recent scientific literature focusing on murine models of DC-based cancer vaccination.
- Analysis of studies investigating antigen sources, adjuvants, and maturing agents in DC vaccination.
- Examination of research on DC subsets and their contribution to anti-tumor immunity.
Main Results:
- Murine models provide valuable insights into the mechanisms of DC-based cancer vaccines.
- Understanding antigen sources, adjuvants, and DC subset interactions is crucial for vaccine design.
- Experimental models highlight both the advantages and limitations of current DC-based vaccination approaches.
Conclusions:
- DC-based vaccination holds significant promise for cancer treatment, with ongoing research focused on optimization.
- Murine models are instrumental in dissecting the complexities of DC-mediated anti-tumor immunity.
- Translational research utilizing insights from murine models is key to developing successful DC-based cancer vaccines.
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...